Company / PP&E (Net)
Jazz Pharmaceuticals PP&E (Net) History
FY2016-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$228.1M
FY2022
5-year range
$228.1M / $256.8M
FY2018-FY2022
Trend
-11.2%
vs FY2021
Sector context
#29 of 193
Health Care
What the data says
Jazz Pharmaceuticals's pp&e (net) of $228M is higher than 85% of companies in the Health Care sector (FY2022). PP&E (Net) has fluctuated over the past 7 years, ranging from $105M in FY2019 to $257M in FY2021.
Based on SEC 10-K filings.
$228M in FY2022 with a 5-year CAGR of +6.0%. Top quartile in the Health Care sector.
Improved from $128M to $228M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +29.5%
- 5-Year CAGR
- +6.0%
- 10-Year CAGR
- -
Sector benchmark
Top 15% in Health CareTop 15% of 193This company $228.1M Sector average $777.6M
▼
-70.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +6.0%, indicating consistent growth.
- In FY2022, pp&e (net) decreased 11.2% year-over-year.
- Ranks #29 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $228.1M | -11.2% |
| FY2021 | $256.8M | +100.8% |
| FY2020 | $127.9M | +21.9% |
| FY2019 | $105.0M | -47.6% |
| FY2018 | $200.4M | +17.8% |
| FY2017 | $170.1M | +58.2% |
| FY2016 | $107.5M | +25.6% |
As of FY2022 · SEC 10-K · Updated Jun 30, 2026